Gerresheimer Draws a Crowd for Centor Sale as New Technology Deal Offers Operational Lift

The Düsseldorf-based packaging specialist is navigating one of the most challenging periods in its history, but two developments this week suggest the company may be turning a corner. A divestiture process that could reshape its balance sheet is attracting double-digit bidder interest, while a newly announced technology partnership promises to strengthen its core pharmaceutical packaging business.

Centor Auction Heats Up

Gerresheimer’s sale of its US subsidiary Centor Inc. has drawn ten or more potential buyers, according to company sources. Chief Financial Officer Wolf Lehmann formally launched the process, and the strong response signals that the market views Centor as a quality asset despite the parent company’s troubles. Morgan Stanley is managing the transaction, with completion targeted by the end of 2026.

The proceeds are earmarked for debt reduction — a non-negotiable priority. Gerresheimer’s lenders have extended the deadline for its audited 2025 annual report to September 30, 2026, giving management breathing room. The company itself expects to publish the certified accounts by June, a moment that will either restore or further erode market confidence.

LeneX UltraGuard: Thinner Walls, Stronger Protection

Away from the balance sheet firefighting, Gerresheimer has struck a technology partnership with US firm Milliken centered on a proprietary additive system called LeneX UltraGuard. The innovation improves polymer properties for pharmaceutical containers, delivering up to 40 percent better moisture protection while allowing thinner walls and material savings — all without compromising drug safety standards.

The recently integrated Bormioli Pharma subsidiary already uses the technology for a global client, giving Gerresheimer a head start. The partners plan to showcase the concept at a trade fair in Düsseldorf this May.

Energy Costs Bite Into Margin Target

The operational recovery is not without headwinds. German producer prices posted their steepest monthly increase since August 2022 in March, hitting Gerresheimer as an energy-intensive manufacturer. Energy costs alone rose 7.5 percent.

Should investors sell immediately? Or is it worth buying Gerresheimer?

Whether the company can pass these increases on to its pharmaceutical and food-industry customers will determine whether its 2026 adjusted EBITDA margin target of 18 to 19 percent remains achievable. Management has held revenue guidance steady at €2.3 billion to €2.4 billion.

Legal Pressure Mounts on Former Executives

Meanwhile, the legal front is intensifying. The German Association for the Protection of Securities Holders (DSW) is examining liability claims against former CEO Dietmar Siemssen and former CFO Bernd Metzner over prior-year accounting errors. The DSW is considering bringing in a litigation funder to pursue the case.

The current management team must rebuild trust while the shadow of predecessor misconduct lingers — a delicate balancing act.

Stock Recovers, But the Mountain Remains

The shares have rallied to around €22.30, a 43 percent gain from February’s 52-week low of €15.57. Yet the year-to-date picture remains grim, with a decline of nearly 59 percent. Investors are pricing in a turnaround, but the June audited results will be the real test.

If the Centor sale fetches an attractive price and the certified accounts land without fresh surprises, the new management will have two concrete proofs that the restructuring is gaining traction. Until then, the company operates on borrowed time — literally and figuratively.